Ranger Investment Management L.P. Lowers Stake in LeMaitre Vascular, Inc. $LMAT

Ranger Investment Management L.P. lessened its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 36.8% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 238,360 shares of the medical instruments supplier’s stock after selling 138,672 shares during the period. LeMaitre Vascular comprises about 1.9% of Ranger Investment Management L.P.’s holdings, making the stock its 16th biggest position. Ranger Investment Management L.P.’s holdings in LeMaitre Vascular were worth $26,022,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of LMAT. Sound Income Strategies LLC boosted its position in LeMaitre Vascular by 425.6% during the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 183 shares during the last quarter. Catalyst Capital Advisors LLC acquired a new position in LeMaitre Vascular in the 1st quarter valued at $32,000. Geneos Wealth Management Inc. lifted its stake in shares of LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 398 shares during the period. EverSource Wealth Advisors LLC purchased a new position in shares of LeMaitre Vascular during the 2nd quarter worth $47,000. Finally, GAMMA Investing LLC boosted its holdings in shares of LeMaitre Vascular by 32.7% during the fourth quarter. GAMMA Investing LLC now owns 727 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 179 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Insider Transactions at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,928 shares of the firm’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $107.00, for a total value of $313,296.00. Following the transaction, the insider owned 3,749 shares of the company’s stock, valued at approximately $401,143. This trade represents a 43.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Bridget A. Ross sold 5,044 shares of LeMaitre Vascular stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $111.10, for a total transaction of $560,388.40. Following the transaction, the director owned 3,942 shares in the company, valued at $437,956.20. The trade was a 56.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 54,453 shares of company stock valued at $5,906,174 over the last 90 days. Corporate insiders own 7.40% of the company’s stock.

LeMaitre Vascular Stock Up 3.4%

Shares of NASDAQ:LMAT opened at $102.30 on Wednesday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32. LeMaitre Vascular, Inc. has a 1 year low of $79.00 and a 1 year high of $118.01. The stock has a market capitalization of $2.34 billion, a P/E ratio of 37.75, a PEG ratio of 2.75 and a beta of 0.52. The stock has a 50-day simple moving average of $96.99 and a 200-day simple moving average of $99.38.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The firm had revenue of $66.55 million during the quarter, compared to the consensus estimate of $66.67 million. During the same quarter in the prior year, the company earned $0.48 EPS. The company’s revenue was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Equities analysts forecast that LeMaitre Vascular, Inc. will post 3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on LMAT. Barrington Research reiterated an “outperform” rating and issued a $120.00 target price on shares of LeMaitre Vascular in a research note on Wednesday, June 3rd. Wells Fargo & Company raised their price target on LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. Wall Street Zen upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, July 4th. Citigroup reaffirmed a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Finally, Freedom Capital raised shares of LeMaitre Vascular to a “hold” rating in a research report on Tuesday, March 31st. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $112.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.